Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Merck
Moodys
Mallinckrodt
McKinsey
Boehringer Ingelheim
Johnson and Johnson

Last Updated: May 26, 2022

CLINICAL TRIALS PROFILE FOR BRIMONIDINE TARTRATE


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Brimonidine Tartrate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00061529 ↗ A Phase III Study of Brimonidine Tartrate Ophthalmic Solution, 0.15% in Patients With Open-Angle Glaucoma or Ocular Hypertension Completed Alcon Research Phase 3 2003-01-01 The primary objective of this study is to compare the safety and efficacy of Brimonidine Tartrate Ophthalmic Solution, 0.15% in patients with open-angle glaucoma or ocular hypertension.
NCT00121147 ↗ Additivity Study: Additive Effect on Eye Pressure of Azopt and Alphagan P to Travatan Completed Alcon Research N/A 2003-09-01 The purpose of this study is to compare the additive effect on eye pressure of Azopt and Alphagan P to Travatan.
NCT00121147 ↗ Additivity Study: Additive Effect on Eye Pressure of Azopt and Alphagan P to Travatan Completed Hermann Eye Center N/A 2003-09-01 The purpose of this study is to compare the additive effect on eye pressure of Azopt and Alphagan P to Travatan.
NCT00312416 ↗ Effects of Topical Clonidine vs. Brimonidine on Choroidal Blood Flow and Intraocular Pressure During Isometric Exercise Completed Medical University of Vienna Phase 4 2004-02-01 Brimonidine tartrate is an alpha-2 agonist ocular hypotensive drug that exerts its effect by causing both a decrease in aqueous production and an increase in uveoscleral outflow. It has been proven to reduce increased intraocular pressure in glaucoma and ocular hypertension. As an alpha 2 agonist Brimonidine belongs to the same class of drugs as Clonidine; however, its molecular structure is sufficiently different to make it more selective for the alpha 2 receptor than Clonidine. Unlike Clonidine, Brimonidine does not appear to have an effect on the central nervous system and therefore does not cause sedation or systemic hypotension. In addition to their known effect of lowering intraocular pressure, alpha 2 adrenoceptor agonists are neuroprotective. It has, however, been shown that Brimonidine is a very potent vasoconstrictor in the ciliary body thus reducing aqueous humor production. Little is, however, known about potential vasoconstrictor effects of Brimonidine in the posterior pole of the eye. This is of clinical importance, because optic nerve head ischemia appears to contribute to glaucoma pathophysiology. This study is performed to investigate the effects of topical Clonidine vs. topical Brimonidine on choroidal blood flow and intraocular pressure during isometric exercise.
NCT00413751 ↗ Effect of Brimonidine Tartrate Ophthalmic Solution 0.15% on Pupil Diameter in Normal Eyes Completed Walter Reed Army Medical Center 1969-12-31 The objective of this study is to evaluate the effect of brimonidine tartrate ophthalmic solution 0.15% (Alphagan P) on pupil diameter under different luminance conditions.
NCT00435058 ↗ Visual Function Changes After Intraocular Pressure Reduction Completed University of Sao Paulo N/A 2005-09-01 During the glaucomatous disease process, subpopulations of cells may be dead, damaged or healthy. Visual function changes could be observed due to a recovering of the suffering ganglion cells after the intraocular pressure reduction. This study aims at evaluating the correlation between intraocular pressure reduction and visual function changes in glaucoma patients after using antiglaucoma medications.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Brimonidine Tartrate

Condition Name

Condition Name for Brimonidine Tartrate
Intervention Trials
Ocular Hypertension 14
Glaucoma 9
Glaucoma, Open-Angle 7
Hyperemia 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Brimonidine Tartrate
Intervention Trials
Glaucoma 21
Ocular Hypertension 15
Glaucoma, Open-Angle 14
Hypertension 13
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Brimonidine Tartrate

Trials by Country

Trials by Country for Brimonidine Tartrate
Location Trials
United States 80
Korea, Republic of 4
Brazil 4
India 3
United Kingdom 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Brimonidine Tartrate
Location Trials
Pennsylvania 7
California 7
Massachusetts 5
Florida 5
Texas 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Brimonidine Tartrate

Clinical Trial Phase

Clinical Trial Phase for Brimonidine Tartrate
Clinical Trial Phase Trials
Phase 4 16
Phase 3 13
Phase 2 8
[disabled in preview] 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Brimonidine Tartrate
Clinical Trial Phase Trials
Completed 42
Not yet recruiting 3
Withdrawn 2
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Brimonidine Tartrate

Sponsor Name

Sponsor Name for Brimonidine Tartrate
Sponsor Trials
Allergan 14
ORA, Inc. 4
Bausch & Lomb Incorporated 3
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Brimonidine Tartrate
Sponsor Trials
Industry 38
Other 24
U.S. Fed 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Harvard Business School
Merck
Medtronic
McKinsey
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.